Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, ...
Niclosamide is an old antiparasitic with documented anticancer activity in laboratory models, but its clinical use for cancer has been limited by poor solubility and bioavailability. The authors ...
Two canine osteosarcoma patients who underwent amputations are shown in 2023, when their care team and owners celebrated their final chemo treatments by ringing a bell and giving both dogs lots of ...
OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...
(RTTNews) - OS Therapies Inc. (OSTX) Thursday announced positive data for OST-HER2 in combination with palliative radiation in dogs with unresected appendicular osteosarcoma. Results from the study ...
Researchers from UC Davis and Lawrence Livermore National Laboratory developed and studied a new material — engineered bone marrow, or eBM. Engineered bone marrow offers a better way to study ...
U.S. Department of Agriculture Center for Veterinary Biologics approves ECI®, a first-in-class adoptive cell therapy for the treatment of bone cancer in dogs ECI® is now available at 100 authorized ...
LENEXA, Kan., June 19, 2025 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical study evaluating ELIAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results